TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Vera Therapeutics (VERA) Gets a Buy From TD Cowen
Vera Therapeutics Analyst Ratings
Jefferies Initiates Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $53
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $70
Vera Therapeutics' Atacicept: Promising Clinical Data and Strategic Expansion Fuel Buy Rating
Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $107
Vera Therapeutics Analyst Ratings
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $107
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $72
Vera Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $62
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $62
Vera Therapeutics' Atacicept Secures Buy Rating Amid Strong Financials and Promising Clinical Trials
Wedbush Cuts Vera Therapeutics' Price Target to $30 From $32, Maintains Neutral Rating
Vera Therapeutics Analyst Ratings
Komo: Maintaining the Vera Therapeutics (VERA.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $60.00 to $65.00.